PULMONX CORP (LUNG) Stock Fundamental Analysis

NASDAQ:LUNG • US7458481014

1.445 USD
+0.03 (+1.76%)
Last: Feb 19, 2026, 01:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, LUNG scores 3 out of 10 in our fundamental rating. LUNG was compared to 185 industry peers in the Health Care Equipment & Supplies industry. LUNG may be in some trouble as it scores bad on both profitability and health. LUNG is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • LUNG had negative earnings in the past year.
  • In the past year LUNG has reported a negative cash flow from operations.
  • In the past 5 years LUNG always reported negative net income.
  • LUNG had a negative operating cash flow in each of the past 5 years.
LUNG Yearly Net Income VS EBIT VS OCF VS FCFLUNG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -41.04%, LUNG is doing worse than 64.32% of the companies in the same industry.
  • LUNG's Return On Equity of -94.54% is on the low side compared to the rest of the industry. LUNG is outperformed by 61.62% of its industry peers.
Industry RankSector Rank
ROA -41.04%
ROE -94.54%
ROIC N/A
ROA(3y)-33.09%
ROA(5y)-26.44%
ROE(3y)-51.8%
ROE(5y)-38.97%
ROIC(3y)N/A
ROIC(5y)N/A
LUNG Yearly ROA, ROE, ROICLUNG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

  • The Gross Margin of LUNG (73.30%) is better than 83.24% of its industry peers.
  • LUNG's Gross Margin has been stable in the last couple of years.
  • LUNG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.3%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.19%
GM growth 5Y1.48%
LUNG Yearly Profit, Operating, Gross MarginsLUNG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • LUNG does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, LUNG has more shares outstanding
  • LUNG has more shares outstanding than it did 5 years ago.
  • LUNG has a worse debt/assets ratio than last year.
LUNG Yearly Shares OutstandingLUNG Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
LUNG Yearly Total Debt VS Total AssetsLUNG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • LUNG has an Altman-Z score of -4.66. This is a bad value and indicates that LUNG is not financially healthy and even has some risk of bankruptcy.
  • LUNG has a Altman-Z score of -4.66. This is in the lower half of the industry: LUNG underperforms 67.57% of its industry peers.
  • A Debt/Equity ratio of 0.62 indicates that LUNG is somewhat dependend on debt financing.
  • LUNG has a Debt to Equity ratio of 0.62. This is in the lower half of the industry: LUNG underperforms 62.70% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF N/A
Altman-Z -4.66
ROIC/WACCN/A
WACC10.8%
LUNG Yearly LT Debt VS Equity VS FCFLUNG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

  • LUNG has a Current Ratio of 4.86. This indicates that LUNG is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of LUNG (4.86) is better than 77.30% of its industry peers.
  • LUNG has a Quick Ratio of 4.15. This indicates that LUNG is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of LUNG (4.15) is better than 76.22% of its industry peers.
Industry RankSector Rank
Current Ratio 4.86
Quick Ratio 4.15
LUNG Yearly Current Assets VS Current LiabilitesLUNG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • LUNG shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.40%.
  • Looking at the last year, LUNG shows a quite strong growth in Revenue. The Revenue has grown by 15.59% in the last year.
  • Measured over the past years, LUNG shows a very strong growth in Revenue. The Revenue has been growing by 20.78% on average per year.
EPS 1Y (TTM)1.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.56%
Revenue 1Y (TTM)15.59%
Revenue growth 3Y20.06%
Revenue growth 5Y20.78%
Sales Q2Q%5.47%

3.2 Future

  • LUNG is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.48% yearly.
  • LUNG is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 27.14% yearly.
EPS Next Y-7.1%
EPS Next 2Y1.32%
EPS Next 3Y7.71%
EPS Next 5Y25.48%
Revenue Next Year8.99%
Revenue Next 2Y6.99%
Revenue Next 3Y11.66%
Revenue Next 5Y27.14%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LUNG Yearly Revenue VS EstimatesLUNG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
LUNG Yearly EPS VS EstimatesLUNG Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 6 8

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • LUNG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year LUNG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LUNG Price Earnings VS Forward Price EarningsLUNG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LUNG Per share dataLUNG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.32%
EPS Next 3Y7.71%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for LUNG!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PULMONX CORP

NASDAQ:LUNG (2/19/2026, 1:02:57 PM)

1.445

+0.03 (+1.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-12
Earnings (Next)02-25
Inst Owners78.28%
Inst Owner Change6.31%
Ins Owners10.71%
Ins Owner Change36.31%
Market Cap59.61M
Revenue(TTM)91.66M
Net Income(TTM)-56.75M
Analysts80
Price Target5.87 (306.23%)
Short Float %7.65%
Short Ratio4.96
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.26%
Min EPS beat(2)0.21%
Max EPS beat(2)20.32%
EPS beat(4)4
Avg EPS beat(4)13.38%
Min EPS beat(4)0.21%
Max EPS beat(4)27.7%
EPS beat(8)8
Avg EPS beat(8)16.37%
EPS beat(12)12
Avg EPS beat(12)13.5%
EPS beat(16)15
Avg EPS beat(16)10.22%
Revenue beat(2)1
Avg Revenue beat(2)0.34%
Min Revenue beat(2)-0.33%
Max Revenue beat(2)1.01%
Revenue beat(4)3
Avg Revenue beat(4)1.37%
Min Revenue beat(4)-0.33%
Max Revenue beat(4)4.53%
Revenue beat(8)6
Avg Revenue beat(8)1.49%
Revenue beat(12)10
Avg Revenue beat(12)3.14%
Revenue beat(16)11
Avg Revenue beat(16)2.17%
PT rev (1m)0%
PT rev (3m)-14.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.08%
EPS NY rev (1m)0%
EPS NY rev (3m)4.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.25%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.65
P/FCF N/A
P/OCF N/A
P/B 0.99
P/tB 1.03
EV/EBITDA N/A
EPS(TTM)-1.41
EYN/A
EPS(NY)-1.36
Fwd EYN/A
FCF(TTM)-0.78
FCFYN/A
OCF(TTM)-0.77
OCFYN/A
SpS2.22
BVpS1.46
TBVpS1.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -41.04%
ROE -94.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.3%
FCFM N/A
ROA(3y)-33.09%
ROA(5y)-26.44%
ROE(3y)-51.8%
ROE(5y)-38.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.19%
GM growth 5Y1.48%
F-Score2
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 48.92%
Cap/Sales 0.6%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.86
Quick Ratio 4.15
Altman-Z -4.66
F-Score2
WACC10.8%
ROIC/WACCN/A
Cap/Depr(3y)78.82%
Cap/Depr(5y)169.58%
Cap/Sales(3y)1.79%
Cap/Sales(5y)3.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.56%
EPS Next Y-7.1%
EPS Next 2Y1.32%
EPS Next 3Y7.71%
EPS Next 5Y25.48%
Revenue 1Y (TTM)15.59%
Revenue growth 3Y20.06%
Revenue growth 5Y20.78%
Sales Q2Q%5.47%
Revenue Next Year8.99%
Revenue Next 2Y6.99%
Revenue Next 3Y11.66%
Revenue Next 5Y27.14%
EBIT growth 1Y-0.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.15%
EBIT Next 3Y19.16%
EBIT Next 5Y8.94%
FCF growth 1Y18.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y18.3%
OCF growth 3YN/A
OCF growth 5YN/A

PULMONX CORP / LUNG FAQ

What is the fundamental rating for LUNG stock?

ChartMill assigns a fundamental rating of 3 / 10 to LUNG.


Can you provide the valuation status for PULMONX CORP?

ChartMill assigns a valuation rating of 0 / 10 to PULMONX CORP (LUNG). This can be considered as Overvalued.


Can you provide the profitability details for PULMONX CORP?

PULMONX CORP (LUNG) has a profitability rating of 1 / 10.


What is the financial health of PULMONX CORP (LUNG) stock?

The financial health rating of PULMONX CORP (LUNG) is 3 / 10.


Can you provide the expected EPS growth for LUNG stock?

The Earnings per Share (EPS) of PULMONX CORP (LUNG) is expected to decline by -7.1% in the next year.